2-(4-(4-fluorophenyl)piperazin-1-yl)-2-oxo-N-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)acetamide

ID: ALA4456965

Chembl Id: CHEMBL4456965

PubChem CID: 24809576

Max Phase: Preclinical

Molecular Formula: C19H17FN4O4

Molecular Weight: 384.37

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=C(Nc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCN(c2ccc(F)cc2)CC1

Standard InChI:  InChI=1S/C19H17FN4O4/c20-12-1-4-14(5-2-12)23-7-9-24(10-8-23)18(26)17(25)21-13-3-6-15-16(11-13)28-19(27)22-15/h1-6,11H,7-10H2,(H,21,25)(H,22,27)

Standard InChI Key:  QUEYDMMADATDON-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4456965

   2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 384.37

Molecular Weight (Monoisotopic): 384.1234

AlogP: 1.55

#Rotatable Bonds: 2

Polar Surface Area: 98.65

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.51

CX Basic pKa: 2.83

CX LogP: 2.05

CX LogD: 2.05

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.65

Np Likeness Score: -1.90

References

1. Anan K, Masui M, Tazawa A, Tomida M, Haga Y, Kume M, Yamamoto S, Shinohara S, Tsuji H, Shimada S, Yagi S, Hasebe N, Kai H..  (2019)  Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization.,  29  (9): [PMID:30833109] [10.1016/j.bmcl.2019.02.017]

Source

Source(1):

• Scientific Literature